Circulating cell-free DNA and circulating tumor cells, the “liquid biopsies” in ovarian cancer

Table 2 Detection and prognostic relevance of CTCs in ovarian cancer patients

Year	Sample	Sample timing	NO. Patients	Method of CTCs detection	CTCs Positive Rate	Targeted antigen/gene	Prognostic Significance	Reference
2017	PB	Before surgery	54	Biotin-doped Ppydeposited microfluidic device	98.1%	EpCAM, TROP-2, EGFR, vimentin, and N-cadherin	PFS	[96]
2016	PB	Before surgery	56	Size-dependent seperation	58%	Gene panel including: EpCAM, MUC1, MUC16, CK18, 19, ERCC1	NR	[59]
2014	PB	Before surgery	80	RT-PCR	47.5%	MAGE-As	OS, PFS	[97]
2013	BM	Intra-operative period	456	ICC	27%	A-45B/B3	PFS	[98]
2011	PB	Before 2nd line chemotherapy	216	CellSearch®	14.4%	EpCAM, CK, CD45	OS, PFS	[57]
2011	PB	Before surgery	86	RT-PCR	19%	EpCAM, MUC1, HER2	OS	[99]
2009	PB	Before surgery	71	ICC	60.6%	EpCAM, ESA, CK	PFS	[54]
2009	BM	Intra-operative period	112	ICC	25%	A-45B/B3	PFS	[100]
2008	PM	Before surgery	20	Density gradient/flow cytometry	90%	Folate-AlexaFluor 488 DUPA-FITC	NS	[101]
2007	PB/BM	Before and after chemotherapy.	57(PB)/46(BM)	ICC	21%/54%	A-45B/B3, CK8, 18, 19	OS, PFS	[102]
2006	PB	Before and after surgery	24	Immunomagnetic beads/RT-PCR	75%	BER-EP4	NS	[103]
2003	PB	Before surgery	64	ICC	18.7%	CK7, 8, 18, 20, EGFR	NS	[104]
2002	PB/BM	After surgery and before adjuvant chemotherapy	90(PB)/73(BM)	Immunomagnetic beads	12%//21%	MOC-31	NS	[105]

PB, peripheral blood; BM, bone marrow; NR, not reported; NS, not significance; OS, overall survival; PFS, progression-free survival; RT-PCR, Reverse transcription-polymerase chain reaction; CK, cytokeratin; ICC, immunocytochemistry.

ISSN: 1757-2215